Sitravatinib
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Sitravatinib |
| Trade Name | |
| Synonyms | MGCD516 |
| Drug Descriptions |
Sitravatinib (MGCD516) inhibits several receptor tyrosine kinases including AXL, MET, KIT, VEGFR1-3, TYRO3, RET family members, TRK family members, DDR, and Eph family members, resulting in abrogation of downstream signaling and decreased cell proliferation in tumors overexpressing the target proteins (PMID: 26675259, PMID: 30501104, PMID: 32525624). |
| DrugClasses | AXL Inhibitor 30 DDR1 Inhibitor 10 DDR2 inhibitor 7 KIT Inhibitor 57 MERTK Inhibitor 13 MET Inhibitor 59 RET Inhibitor 53 Trk Receptor Inhibitor (Pan) 33 TYRO3 Inhibitor 7 VEGFR Inhibitor (Pan) 36 |
| CAS Registry Number | 1123837-84-2 |
| NCIT ID | C117734 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Docetaxel + Sitravatinib | Docetaxel Sitravatinib | 0 | 0 |
| Enfortumab vedotin-ejfv + Sitravatinib | Enfortumab vedotin-ejfv Sitravatinib | 0 | 1 |
| Ipilimumab + Nivolumab + Sitravatinib | Ipilimumab Nivolumab Sitravatinib | 0 | 1 |
| Ipilimumab + Sitravatinib | Ipilimumab Sitravatinib | 0 | 1 |
| Nivolumab + Sitravatinib | Nivolumab Sitravatinib | 0 | 8 |
| Pembrolizumab + Sitravatinib | Pembrolizumab Sitravatinib | 0 | 3 |
| Sitravatinib | Sitravatinib | 7 | 4 |
| Sitravatinib + Tislelizumab | Sitravatinib Tislelizumab | 0 | 2 |
CKB BOOST